BIND-014 first nanomedicine to enter clinical studies

BIND-014 is the first targeted and programmed nanomedicine to enter human clinical studies. The Phase 1 study has been electronically published in Science Translational Medicine. BIND-014 is a programmable nanomedicine that combines a targeting ligand and a therapeutic nanoparticle. BIND-014 contains docetaxel, a proven cancer drug which is approved in major cancer indications including breast, prostate and lung, encapsulated in FDA-approved biocompatible and biodegradable polymers. BIND-014 is targeted to prostate specific membrane antigen, a cell surface antigen abundantly expressed on the surface of cancer cells and on new blood vessels that feed a wide array of solid tumors. In preclinical cancer models, BIND-014 was shown to deliver up to ten-fold more docetaxel to tumors than an equivalent dose of conventional docetaxel. The results of the Phase I study is seen as a strong foundation to advance into Phase II development later this year 2012.see Sci Transl Med 4 April 2012: Vol. 4, Issue 128, p. 128ra39 Sci. Transl. Med. DOI: 10.1126/scitranslmed.3003651 "Preclinical Development and Clinical Translation of a PSMA-Targeted Docetaxel Nanoparticle with a Differentiated Pharmacological Profile" -Jeffrey Hrkach et al